Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Mogens Kjaer"'
Autor:
Mogens Thomsen, Mogens Kjaer
Publikováno v:
Acta Pathologica Microbiologica Scandinavica Section C Immunology. :403-413
Thirteen patients with renal carcinoma were examined for tumour-directed, cell-mediated hypersensitivity (TCMH) by means of the leucocyte migration technique, and for general immunocompetence (GIC) by means of quantitation of T- and B-cells in periph
Autor:
Mogens Kjær
Publikováno v:
Acta Neurologica Scandinavica. 59:72-79
Brain stem auditory evoked potentials have been recorded in 40 normal subjects aged 13--48 years, by stimulating monaurally with random stimulus interval. The male subjects have latencies of the waves III-VII, which are significantly longer than fema
Autor:
Mogens Kjær
Publikováno v:
Acta Neurologica Scandinavica. 61:157-166
A total of 158 recordings of brain stem auditory evoked potentials (BAEPs) were obtained in 121 patients with multiple sclerosis. A statistically significant increased incidence of abnormality and diffusely abnormal recordings was found with increasi
Autor:
Mogens Kjær
Publikováno v:
Acta Neurologica Scandinavica. 62:20-33
In examining neurological patients suspected of having a brain stem lesion with brain stem auditory evoked potentials (BAEPs), a technique giving high amplitudes and/or maximal recognizability of most of the components was preferred. An increase of i
Autor:
Mogens Kjaer
Publikováno v:
Allergy. 31:373-415
Autor:
Bent Ejlertsen, Jørn Andersen, Johanna Sjöström, Henning T. Mouridsen, Mogens Kjaer, Sven T Langkjer
Publikováno v:
Ejlertsen, B L, Mouridsen, H T, Langkjer, S T, Andersen, J, Sjöström, J & Kjaer, M 2004, ' Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403) ', Journal of Clinical Oncology, vol. 22, no. 12, pp. 2313-20 . https://doi.org/10.1200/JCO.2004.11.503
Purpose To determine whether the addition of intravenous (IV) vinorelbine to epirubicin increased the progression-free survival in first-line treatment of metastatic breast cancer. Patients and Methods A total of 387 patients were randomly assigned t
Autor:
Jan Erik Frödin, Bengt Glimelius, Nina Keldsen, Mogens Kjaer, Anders Jakobsen, Niels Gyldenkerne, Flemming Hansen, Erik Sandberg, Per Pfeiffer
Publikováno v:
University of Southern Denmark
Gyldenkerne, N, Glimelius, B, Frodin, J E, Kjær, M, Pfeiffer, P, Hansen, F, Keldsen, N, Sandberg, E & Jakobsen, A 2004, ' A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer ', Acta Oncologica, vol. 43, no. 3, pp. 276-279 .
Gyldenkerne, N, Glimelius, B, Frodin, J E, Kjær, M, Pfeiffer, P, Hansen, F, Keldsen, N, Sandberg, E & Jakobsen, A 2004, ' A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer ', Acta Oncologica, vol. 43, no. 3, pp. 276-279 .
The main objectives of this phase II study were to determine efficacy and safety of the combination of UFT with Leucovorin and mitomycin C in patients with metastatic colorectal cancer. Ninety-seven patients were treated with UFT (91 patients 300 mg/
Autor:
Mogens Blichert-Toft, Claus Kamby, Mogens Kjaer, Carsten Rose, Jørgen Johansen, Jens Overgaard, Marie Overgaard, Svend Aage Engelholm, Jens Juul-Christensen, Carl C. Gadeberg
Publikováno v:
Acta Oncologica. 41:369-380
A total of 266 recurrence-free breast cancer patients from the randomized DBCG-82TM breast conservation trial were called in for a follow-up investigation to study the impact of surgical and radiation treatment factors on the cosmetic and functional
Autor:
Mogens Kjær
Publikováno v:
Acta Pathologica Microbiologica Scandinavica Section B Microbiology and Immunology. :294-296
Autor:
H. T. Mouridsen, Marie Overgaard, Carsten Rose, M.B. Jensen, Jørn Andersen, Mogens Kjaer, S. Cold, Martin Andersson, Bent Ejlertsen, Claus Kamby, P. Dombernowsky
Publikováno v:
European Journal of Cancer. 35:1659-1666
Following modified radical mastectomy, pre- and perimenopausal (amenorrhoea for5 years) patients with stage II or III breast cancer received CMF (cyclophosphamide 600, methotrexate 40, 5-fluorouracil 600 mg/m2 intravenously (i.v.) every 4 weeks, 9 cy